Home > Press > ViRexx Announces LM Funds Corp. Excercises Option to Exchange Convertible Loan
Abstract:
ViRexx Medical Corp. (TSX:VIR) (AMEX:REX), a company focused on developing innovative-targeted therapeutic products that offer better quality of life and a renewed hope for living announces that LM Funds Corp. ("LM") has exercised its option to exchange its convertible loan issued to ViRexx June 4, 2008 into common shares of ViRexx.
ViRexx Announces LM Funds Corp. Excercises Option to Exchange Convertible Loan
Edmonton, AB, Canada | Posted on September 19th, 2008
As a result of LM's conversion it has received 10,000,000 common shares of ViRexx at a price per share of CA$0.10. Each common share issued in this conversion is accompanied by a one-half warrant. Each full warrant entitles the holder, on exercise to purchase one additional common share at a price equal to CA$0.15 for 12 months from the date of issue of the warrant, September 17, 2008.
With this conversion, the General Security Agreement ("GSA") covering as security all of ViRexx's present and after acquired property and intellectual property, subject to some possible third party interests in the patents has been relieved and released.
"This is a positive first step for ViRexx as the company moves forward and we now have the freedom to use our assets to further the long term value and interests of ViRexx" said Darrell Elliott, Chairman and Interim Chief Executive Officer of ViRexx.
####
About ViRexx Medical Corp.
ViRexx is a Canadian-based development-stage biotech company focused on developing innovative-targeted therapeutic products that offer better quality of life and a renewed hope for living. Our platform technologies include product candidates for the treatment of Hepatitis B, Hepatitis C, avian influenza viral infections, biodefence and nanoparticle applications, select solid tumors and late-stage ovarian cancer.
This news release contains certain forward-looking statements that reflect the current views and/or expectations of the Company with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
The TSX has not approved or disapproved of the information contained herein.
For more information, please click here
Contacts:
ViRexx Medical Corp.
Darrell Elliott
Chairman and Chief Executive Officer
(780) 433-4411
(780) 436-0068 (FAX)
Copyright © Marketwire
If you have a comment, please
Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
News and information
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013
VC/Funding/Angel financing/Loans/Leases/Crowdfunding
Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG June 17th, 2013
Long Island Capital Alliance Announces Participants for Biotech Technology Transfer Capital Forum: Event to Be Held on June 14 in Collaboration With Cold Spring Harbor Laboratory June 8th, 2013
CRIXlabs Joins the ROCK Health Incubator: ROCK Health is the world’s leading healthcare incubator looking to make meaningful change through scalable, innovative technology. June 5th, 2013
Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home: Glowing Plant seeks funds via crowdfunding and raises almost $400,000 May 31st, 2013
Investments/IPO's/Splits
Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG June 17th, 2013
Harris & Harris Group Notes Carl Zeiss' Planned Acquisition of Xradia June 13th, 2013
Long Island Capital Alliance Announces Participants for Biotech Technology Transfer Capital Forum: Event to Be Held on June 14 in Collaboration With Cold Spring Harbor Laboratory June 8th, 2013
Iran to Hold Int'l Forum on Nanotechnology Economy (IFNE2013) May 30th, 2013
Nanomedicine
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013
European Technology Platform for Nanomedicine and Nanomed2020 European Consortium Launch the Nanomedicine Award June 17th, 2013
Announcements
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013